Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Shweta, Urva"'
Autor:
Karen Schneck, Shweta Urva
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 13, Iss 3, Pp 494-503 (2024)
Abstract Tirzepatide is a first‐in‐class glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist approved as for the treatment of type 2 diabetes mellitus. A population‐based pharmacokinetic (PK) model wa
Externí odkaz:
https://doaj.org/article/fb3b81682750428da2ed990b59795c31
Autor:
Dipak R. Patel, Shweta Urva, Stephen Ho, Cody J. Buckman, Yanfei Ma, Jean Lim, Sean E. Sissons, Mary S. Zuniga, Diane Philips, Karen Cox, Daniel J. Dairaghi
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 3, Pp 1037-1048 (2021)
Abstract LY2775240 is a highly selective, potent and orally‐administered inhibitor of phosphodiesterase 4 (PDE4), and is being investigated as a treatment option for inflammatory disorders, such as psoriasis. LY2775240 was investigated in rodent an
Externí odkaz:
https://doaj.org/article/26338cb3724a46be895644ae7734a730
Autor:
Tamer Coskun, Kyle W. Sloop, Corina Loghin, Jorge Alsina-Fernandez, Shweta Urva, Krister B. Bokvist, Xuewei Cui, Daniel A. Briere, Over Cabrera, William C. Roell, Uma Kuchibhotla, Julie S. Moyers, Charles T. Benson, Ruth E. Gimeno, David A. D'Alessio, Axel Haupt
Publikováno v:
Molecular Metabolism, Vol 18, Iss , Pp 3-14 (2018)
Objective: A novel dual GIP and GLP-1 receptor agonist, LY3298176, was developed to determine whether the metabolic action of GIP adds to the established clinical benefits of selective GLP-1 receptor agonists in type 2 diabetes mellitus (T2DM). Metho
Externí odkaz:
https://doaj.org/article/e80aeca8145a4ac5b361969b75b1dc5e
Autor:
Tim Heise, J. Hans DeVries, Shweta Urva, Jing Li, Edward J. Pratt, Melissa K. Thomas, Kieren J. Mather, Chrisanthi A. Karanikas, Julia Dunn, Axel Haupt, Zvonko Milicevic, Tamer Coskun
Publikováno v:
Diabetes Care. 46:998-1004
OBJECTIVE To evaluate the effects of tirzepatide on body composition, appetite, and energy intake to address the potential mechanisms involved in body weight loss with tirzepatide. RESEARCH DESIGN AND METHODS In a secondary analysis of a randomized,
Autor:
Shweta, Urva, Tamer, Coskun, Mei Teng, Loh, Yu, Du, Melissa K, Thomas, Sirel, Gurbuz, Axel, Haupt, Charles T, Benson, Martha, Hernandez-Illas, David A, D'Alessio, Zvonko, Milicevic
Publikováno v:
The Lancet. 400:1869-1881
Treating hyperglycaemia and obesity in individuals with type 2 diabetes using multi-receptor agonists can improve short-term and long-term outcomes. LY3437943 is a single peptide with agonist activity for glucagon, glucose-dependent insulinotropic po
Autor:
Francis S. Willard, Jonathan D. Douros, Maria B.N. Gabe, Aaron D. Showalter, David B. Wainscott, Todd M. Suter, Megan E. Capozzi, Wijnand J.C. van der Velden, Cynthia Stutsman, Guemalli R. Cardona, Shweta Urva, Paul J. Emmerson, Jens J. Holst, David A. D’Alessio, Matthew P. Coghlan, Mette M. Rosenkilde, Jonathan E. Campbell, Kyle W. Sloop
Publikováno v:
JCI Insight, Vol 5, Iss 17 (2020)
Tirzepatide (LY3298176) is a dual GIP and GLP-1 receptor agonist under development for the treatment of type 2 diabetes mellitus (T2DM), obesity, and nonalcoholic steatohepatitis. Early phase trials in T2DM indicate that tirzepatide improves clinical
Externí odkaz:
https://doaj.org/article/03002ae150b14972b6d0c404574ecbbd
Autor:
Tim Heise, J Hans DeVries, Shweta Urva, Jing Li, Edward John Pratt, Melissa K. Thomas, Kieren Mather, Julia Dunn, Axel Haupt, Zvonko Milicevic, Tamer Coskun
Publikováno v:
Diabetologie und Stoffwechsel.
Autor:
Tamer Coskun, Zvonko Milicevic, Axel Haupt, Julia Dunn, Chrisanthi A. Karanikas, Kieren J. Mather, Melissa K. Thomas, Edward J. Pratt, Jing Li, Shweta Urva, J Hans DeVries, Tim Heise
OBJECTIVE: To evaluate effects of tirzepatide on body composition, appetite and energy intake to address the potential mechanisms involved in body weight loss with tirzepatide. RESEARCH DESIGN AND METHODS: In a secondary analysis of a randomized, dou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8174afe34e453bf3a6daeece5fa35b3d
https://doi.org/10.2337/figshare.21984596.v1
https://doi.org/10.2337/figshare.21984596.v1
Autor:
Andrea Bauer, Philippe Berben, Sudhir S. Chakravarthi, Sayantan Chattorraj, Ashish Garg, Betty Gourdon, Tycho Heimbach, Ye Huang, Christopher Morrison, Deepak Mundhra, Ramesh Palaparthy, Pratik Saha, Maxime Siemons, Naveed A. Shaik, Yi Shi, Sara Shum, Naveen K. Thakral, Shweta Urva, Ryan Vargo, Venkat R. Koganti, Stephanie E. Barrett
Publikováno v:
Pharmaceutical Research.
Autor:
Sean E. Sissons, Cody J. Buckman, Mary S. Zuniga, Shweta Urva, Karen Cox, Yanfei Ma, Stephen Ho, Diane Philips, Jean Lim, Dipak R. Patel, Daniel J. Dairaghi
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 3, Pp 1037-1048 (2021)
Clinical and Translational Science
Clinical and Translational Science
LY2775240 is a highly selective, potent and orally‐administered inhibitor of phosphodiesterase 4 (PDE4), and is being investigated as a treatment option for inflammatory disorders, such as psoriasis. LY2775240 was investigated in rodent and rhesus